In December 2018, the Board of Directors approved our Reinvent SEE business transformation, including the related restructuring program (“Reinvent SEE Program”), which concluded as of the end of calendar year 2022.

On August 7, 2023, the Board of Directors approved the 3-year cost take-out to grow program (“CTO2Grow Program”). The total cash cost of this program is estimated to be $160 million.

For the year ended December 31, 2024, the Company incurred cash expense including $58.0 million of restructuring charges related to headcount reductions and $30.1 million of other associated costs for the CTO2Grow Program. For the year ended December 31, 2024, the Company incurred non-cash expense of approximately $5.6 million for other associated costs primarily related to the impairment of property and equipment associated with the CTO2Grow Program.

For the year ended December 31, 2023, the Company incurred cash expense including $16.9 million of restructuring charges related to headcount reductions, $14.6 million of costs associated with contract terminations, and $1.7 million of other associated costs in connection with the CTO2Grow Program. For the year ended December 31, 2023, the Company incurred non-cash expense of approximately $32.6 million for other associated costs primarily related to the impairment of property and equipment and inventory obsolescence charges associated with the Kevothermal and plant-based rollstock business closures under the CTO2Grow Program.


(In millions)	Total Restructuring Program			Less Program Activity to Date		Remaining Restructuring

Costs of reduction in headcount as a result of reorganization		$	90	$	(75)		$	15
Other associated costs		45		(26)			19
Contract terminations		20		(15)			5
Total cash expense		$	155	$	(116)		$	39
Capital expenditures		5		(2)			3
Total estimated cash cost(1)		$	160	$	(118)		$	42
Total estimated non-cash expense(2)		$	38	$	(38)		$	—
Total estimated expense(3)		$	193	$	(154)		$	39

(2)Reflects actual expenses that have been incurred. Ranges associated with future non-cash expenses related to the CTO2Grow Program are difficult to estimate and are not available without unreasonable efforts, as these typically relate to exit and disposal activities.

The Company also has restructuring programs related to acquisitions. We recorded less than $1 million of expenses related to these programs within Restructuring charges in our Consolidated Statements of Operations during the years ended December 31, 2024, 2023 and 2022. See Note 5, "Acquisitions," for additional information related to recent acquisitions.


	Year Ended December 31,
(In millions)	2024		2023		2022

Other associated costs	$	30.3	$	34.5	$	9.3
Contract terminations	(0.1)		14.6		—
Restructuring charges	57.8		15.6		12.1


Total charges	$	88.0	$	64.7	$	21.4
Capital expenditures	$	2.3	$	0.4	$	9.7

The aggregate restructuring accrual, spending and other activity for the years ended December 31, 2024, 2023 and 2022 and the accrual balance remaining at those year-ends were as follows:


(In millions)












Restructuring accrual at December 31, 2021	$	11.3
Accrual and accrual adjustments	12.1
Cash payments during 2022	(8.6)
Effect of changes in foreign currency exchange rates	(0.1)
Restructuring accrual at December 31, 2022	$	14.7
Headcount accrual and accrual adjustments	15.6
Contract termination accrual and adjustments	11.0
Cash payments during 2023	(17.2)
Effect of changes in foreign currency exchange rates	0.2
Restructuring accrual at December 31, 2023	$	24.3
Headcount accrual and accrual adjustments	57.8

Cash payments during 2024	(37.5)
Effect of changes in foreign currency exchange rates	(1.0)
Restructuring accrual at December 31, 2024	$	43.6

We expect to pay $42.6 million of the accrual balance remaining at December 31, 2024 within the next twelve months. This amount is included in Accrued restructuring costs on the Consolidated Balance Sheets at December 31, 2024. The remaining accrual of $1.0 million is expected to be paid primarily in 2026. This amount is included in Other non-current liabilities on our Consolidated Balance Sheets at December 31, 2024.

The CTO2Grow Program was approved by our Board of Directors as a consolidated program benefiting both Food and Protective, and accordingly the expected program spend by reporting segment is not available. However, of the total restructuring accrual of $43.6 million as of December 31, 2024, $23.3 million was attributable to Food and $20.3 million was attributable to Protective.

In July 2023, the Board of Directors approved a plan to cease operating the Kevothermal temperature assurance business, which resulted in the closure of both the Albuquerque, New Mexico and Hereford, United Kingdom facilities. The decision to cease operations of the Kevothermal business, which is reported in our Protective segment, was triggered by lower volumes and declining financial performance.

In September 2023, the Board of Directors approved a plan to cease operating the plant-based rollstock business and line located in Simpsonville, South Carolina. The decision to cease operations for the plant-based rollstock business, which is reported in our Food segment, was triggered by lower demand for our product due to competitive alternatives in the market. We ceased full manufacturing operations in 2024.

For the year ended December 31, 2023, we recorded $54.1 million of closure charges as part of the CTO2Grow Program primarily associated with Kevothermal, the plant-based rollstock business, and other activities, which included $25.8 million of impairment related to property and equipment, $14.6 million of contract terminations, $6.6 million of inventory obsolescence charges and $7.1 million of severance and other closure related costs. The closure charges, excluding the severance related costs, are reflected within (Loss) Gain on disposal and sale of businesses and property and equipment, net on the Consolidated Statements of Operations. The severance related charges are reflected in Restructuring charges on the Consolidated Statements of Operations. Of the $54.1 million of closure charges, $32.6 million were non-cash.